AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymphoma patients over 65.

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence ...

ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia By Angus Liu Dec 8, 2024 11:00am AstraZeneca ASH 2024 Calquence chronic lymphocytic leukemia ...

RELATED: ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice So far, Imbruvica’s still the king in the BTK class, as AbbVie reported revenues ...

AstraZeneca’s Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for the treatment of adult patients with previously untreated ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...

(RTTNews) - China's National Medical Products Administration approved AstraZeneca plc.'s (AZN, AZN.L)Calquence or acalabrutinib for the treatment of adult patients with chronic lymphocytic ...

AstraZeneca PLC said Monday that its Calquence drug showed greater safety than an existing drug without compromising efficacy in a phase 3 trial with adults with previously treated, high-risk ...

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).